To explore the potential of targeting the ESSENCE–CAD–ferroptosis axis in restraining CRC development, we conducted cell growth experiments using both selumetinib (MEK inhibitor, SEL) and sulfasalazine (ferroptosis inducer, SAS) to impede CRC cells’ growth. The gene discussed is MAP2K7; the disease is colorectal carcinoma.